Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study | Synapse
April 25, 2026
Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study
Key Points
This research aims to compare the efficacy and safety of the biosimilar BAT2506 to the reference drug golimumab in treating active psoriatic arthritis.
Phase 3, multicenter, double-blind, randomized, parallel-group study with patients diagnosed with active psoriatic arthritis.
Patients received either BAT2506 or golimumab over a 24-week period.
Study registered under NCT05046431.
BAT2506 demonstrated comparable efficacy to golimumab, with significant improvements in disease activity measures.
Safety profiles were similar between BAT2506 and golimumab, with no unexpected adverse events reported.
Detailed statistical outcomes are pending further analysis.